Back to top
more

Range Cancer Therapeutics ETF: (CNCR)

(Delayed Data from NASDAQ) As of May 1, 2025 03:29 PM ET

$9.93 USD

9.925
1,441

-0.09 (-0.85%)

Volume: 1,441

Zacks ETF Rank

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

3 - Hold of 5     3    

ETF Quote Details

Previous Close 10.01
Open 10.05
Bid 9.89
Ask 9.99
Day Low-High 9.83-10.05
52wk Low-High 7.88-16.27
Volume 1,441
NAV (month end) 9.42
Premium (+)/Discount (-) (month end)+0.59

Zacks Premium Research for CNCR

Zacks ETF Rank

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

 Hold 3
ETF Risk

Zacks proprietary quantitative models divide each set of ETFs following a similar investment strategy (style box/industry/asset class) into three risk categories- High, Medium, and Low. The aim of our models is to select the best ETFs within each risk category, so that investors can pick an ETF that matches their particular risk preference in order to better achieve their investment goals.

High
ETF Report

ETF Expense Ratio

Expense Ratio 0.79%
Dividend (Yield) $0.00 (0.00%)
Issuer RANGE

Benchmark for CNCR

RANGE ONCOLOGY THERAPEUTICS INDEX

The Range Oncology Therapeutics Index seeks to track the performance of an equal weight basket of companies that either have 50% or greater of their commercial revenue from oncology products or 50% or greater of their pipeline value from oncology drugs in development.

Fund Summary for CNCR

RANGE CANCER THERAPEUTICS ETF

The Range Cancer Therapeutics ETF seeks to track the total return performance, before fees and expenses, of the Range Oncology Therapeutics Index.